Interestingly, several studies have focused on the association between a functional polymorphism within EGLN2 and the risk of cancers, including breast cancer, lung cancer, colorectal cancer, gastric cancer, and hepatocellular carcinoma (Che et al., 2014; Hashemi, Danesh, et al., 2018; Li et al., 2017; Wang, Zhang, Zhou, Chen, & Yu, 2014; Zhu, Luo, & Li, 2019; Zhu et al., 2012). This evidence concerns the gene EGLN2 and breast carcinoma.